Although gout is one of the most effectively treated of all rheumatic diseases, it is among the worst-managed diseases long term, as shown by many studies. “Treatments are excellent, yet are dramatically under-utilized,” says Theodore Fields, MD, FACP, rheumatologist, Hospital for Special Surgery (HSS), New York. “This is because some gout patients feel better between…
Rheumatology Drug Updates: Giant Cell Arteritis Relapse Possible if Tocilizumab Discontinued; Plus Updates on Rituximab, Etanercept
GCA Relapse Possible When Discontinuing Tocilizumab In a Phase 2 randomized, controlled trial, tocilizumab, an anti-IL-6 biologic agent, was shown to induce and maintain remission for up to 52 weeks in patients with giant cell arteritis (GCA).1 During this trial, patients with GCA were randomized in a 2:1 ratio to receive 8 mg/kg bodyweight tocilizumab…
Rheumatology Awards, Appointments and Announcements for January 2017
New Rheumatologist at Minnesota Clinic Meghan Scheibe, MD, is pleased with her new position at CentraCare Clinic Rheumatology and Infusion Services, a hospital-based practice in St. Cloud, Minn. “It’s a great practice,” says Dr. Scheibe. “Young, energetic partners and wonderful support staff. I’m seeing four to six new patients a day.” These are patients who had…
Biomedical Research Key to Advancing Clinical Care for Rheumatic Diseases
WASHINGTON, D.C.—The importance of biomedical research to advancing clinical care with the ultimate goal of improving patients’ lives was on display during an ACR Discovery 2016 plenary session at the 2016 ACR/ARHP Annual Meeting. The session offered new ways to think about and treat select rheumatologic diseases, including research showing for the first time the…
Why Keep a Seat at the AMA Table?
As 2017 unfolds—a year when MACRA begins, lawmakers take steps to dismantle the health reform efforts of the past eight years, and political uncertainty is the rule—it is imperative that the ACR leverage its advocacy agenda by maintaining its seat at the American Medical Association’s (AMA’s) House of Delegates (HOD), says Gary Bryant, MD, FACP…
Mesenchymal Stem Cell Therapy May Help Slow, Repair Degenerative Signs of Osteoarthritis, Musculoskeletal Disease
WASHINGTON, D.C.—For patients with osteoarthritis and other age-related musculoskeletal diseases, treatment with mesenchymal stem cells may soon offer a potent way to slow and repair degenerative signs of disease. This is the goal, a goal that is moving from the laboratory to the clinic as results from ongoing randomized clinical trials show the safety and…
The ACR Government Affairs Committee’s Outgoing Chair Urges Members to Continue Advocating for Rheumatology
WASHINGTON, D.C.—Although political polarization in the U.S. has affected many people’s interest in participating in legislative and advocacy efforts that promote their concerns, William Harvey, MD, MSc, the ACR’s (immediate past) chair of the Government Affairs Committee, encouraged rheumatologists and ACR/ARHP members to remain engaged and get involved with the ACR to fight for issues…
How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
WASHINGTON, D.C.—From diagnosis questions to infection risk to treatment decisions, handling giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) comes with a range of challenges for clinicians. Speaking in the ACR Review Course at the 2016 ACR/ARHP Annual Meeting, an expert—Rebecca Manno, MD, MHS, assistant professor of medicine in rheumatology at Johns Hopkins, as well…
How to Diagnose Shoulder Pain
WASHINGTON, D.C.—A 70-year-old woman had been diagnosed with rotator cuff disease three years earlier and received an array of treatments. What she hadn’t received was an X-ray. She’d had an MRI, and her doctor—not an orthopedist or a rheumatologist, but a primary care physician—had zeroed in on degenerative changes in her rotator cuff. The problem,…
FDA Releases Biosimilar Guidance, Medicare Will Cover Infliximab-dyyb & More
The FDA has released guidance for the development of biosimilars, and Medicare will cover Inflectra (infliximab-dyyb) in 2017…
- « Previous Page
- 1
- …
- 416
- 417
- 418
- 419
- 420
- …
- 777
- Next Page »